News

News

AURELIUS EUROPEAN OPPORTUNITIES IV 

29.09.2022  // AURELIUS acquires three European paper mills from Sappi Limited

  • Complex pan-European carve-out includes site locations in Finland, Germany and the Netherlands
  • Expected combined FY22 revenues of more than EUR 1 bn
  • AURELIUS to support operational development and build-up functions post carve-out

30.08.2022  // AURELIUS announces the acquisition of Agfa Offset Solutions from the Agfa-Gevaert Group

  •  Worldwide provider of offset print solutions with EUR 748m in revenues
  •  Performance improvement opportunity via focus on innovation and operational efficiency

01.08.2022  // AURELIUS acquires Footasylum from JD Sports

  • British brand renowned for omnichannel retailing of fashion streetwear and sportswear
  • Good trading performance with expected revenues of more than EUR 340m in 2022
  • Significant growth potential to be realised by enhancing digital transformation and strengthening own brands

12.07.2022  // AURELIUS successfully closed the acquisitions of dental bauer and significant parts of Pluradent

Luxembourg/Munich, July 12, 2022 – AURELIUS announces the successfully closed acquisitions of dental bauer and significant parts of Pluradent, two German dental distribution companies. Going forward, AURELIUS strives to develop the integrated companies into a leading European dental distribution platform by providing deep operational expertise.

20.06.2022  // AURELIUS acquires dental bauer and Pluradent in a combined transaction to form leading German dental distribution platform

  • AURELIUS agrees to acquire dental bauer from Linneweh family and Pluradent from self-administration
  • Combination of the two companies creates leading German dental distribution platform with more than EUR 300m in revenues
  • Linneweh family significantly reinvests in new joint platform and will drive growth with support from AURELIUS
  • 6th transaction within the AURELIUS co-investment structure

07.04.2022  // AURELIUS completes acquisition of LloydsPharmacy’s parent company, McKesson UK

Luxembourg/London, April 07, 2022 – AURELIUS is pleased to announce that it has successfully closed the acquisition of McKesson UK. McKesson UK is the parent company of a number of market leading healthcare businesses including LloydsPharmacy, John Bell & Croyden and AAH Pharmaceuticals. This landmark deal marks the fifth completed transaction in less than a year for AURELIUS European Opportunities IV, controlling a 70 % stake and its Co-Investor AURELIUS Equity Opportunities SE & Co. KGaA (ISIN: DE000A0JK2A8), controlling the remaining 30 %.

05.04.2022  // Successful Closing of Ceramic Tile Distributors Acquisition

Luxembourg/London, April 05, 2022 – AURELIUS is pleased to announce the successful closing of the acquisition of Ceramic Tile Distributors (“CTD”) in a carve-out transaction from parent company, Saint-Gobain (ISIN: FR0000125007). This is the fourth acquisition completed by AURELIUS European Opportunities IV, controlling a 70 % stake and its Co-Investor AURELIUS Equity Opportunities SE & Co. KGaA (ISIN: DE000A0JK2A8), controlling the remaining 30 %.

02.03.2022  // AURELIUS successfully closed acquisition of Minova Group

Luxemburg/London, March 02, 2022 – AURELIUS is pleased to announce that it has successfully closed the acquisition of Minova in a global carve-out transaction from Orica Limited, Melbourne, Australia (“Orica” ISIN: AU000000ORI1) for an enterprise value of approx. EUR 114 million. This acquisition marks the third completed transaction by AURELIUS European Opportunities IV, controlling a 70 % stake and its Co-Investor AURELIUS Equity Opportunities SE & Co. KGaA (ISIN: DE000A0JK2A8), controlling the remaining 30 %.

18.02.2022  // AURELIUS acquires Ceramic Tile Distributors, a leading supplier of high-quality tiles

  • AURELIUS acquires Ceramic Tile Distributors (CTD) from Saint-Gobain
  • CTD generated revenues of approximately EUR 120 million in 2021
  • Strong potential to leverage CTD’s UK market-leading position, whilst targeting both organic growth and add-on acquisitions

Legal Information

The information on this website is for informational purposes only. The information on this website is not, and is not intended to be, investment advice nor is it a recommendation to enter into any investment; investors should seek independent investment advice before making any investment decisions. The information on this website does not constitute an offer to buy or sell any investment product or service or to engage in any investment activity, or a solicitation of any investment product or service in any jurisdiction in which Aurelius is not permitted to provide its services or make available any investment product.

Any investment opportunities that Aurelius makes available from time to time will only be available to professional investors and will be subject to separate terms and conditions which will apply. This website and the contents herein are only available to such investors in jurisdictions where Aurelius is permitted to offer its products or services. No other person may rely on the information contained in this website.

For UK recipients

This website has been communicated by Aurelius Investment Advisory Limited (“Aurelius”), an authorised representative for its principal Mirabella Advisers LLP, which is authorized and regulated by the Financial Conduct Authority, FCA FRN 606792.

This website is directed at only those entities who are investment professionals with professional experience in matters relating to the contents of this website or other persons who would be classified as professional investors or eligible counterparties pursuant to the rules of the Financial Conduct Authority. In particular, this website is not available to, and may not be relied on by, any person who is a retail investor. If you are in any doubt as to whether you would be deemed to be a retail investor, please seek professional advice and refrain from accessing this website until such advice has been received.